Many patients with dystonia or spasticity who receive botulinum neurotoxin type A (BoNT/A) develop neutralizing antibodies (NABs) to the toxin over time, new research shows. NABs against BoNT/A occur ...

VANCOUVER -- Guidelines for the use of botulinum toxin in various neurological disorders are getting an update, with the best evidence supporting the use of some formulations in spasticity and chronic ...

Medical education and research, diversity in medicine, women in medicine, community engagement and health equity, clinical trials, treatment of rare neurologic disorders, spasticity and dystonia.

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research. The ...

May 9, 2008 – Three new guidelines documents from the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) review the use of botulinum neurotoxin (BoNT) in ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- In ...

Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications - cervical ...

Allergan announced that the Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of lower limb spasticity in adults to decrease the severity of increased muscle ...

VANCOUVER, BRITISH COLUMBIA - The American Academy of Neurology (AAN) has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine ...